BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. ✅
Antibiotics (Basel, Switzerland) (Antibiotics (Basel) ) Vol: 10 Issue 6 Pages: Pub: 2021 May 29 Epub: 2021 May 29 Authors Ridyard KE , Overhage J , |
|
|
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. ✅
Antibiotics (Basel, Switzerland) (Antibiotics (Basel) ) Vol: 10 Issue 6 Pages: Pub: 2021 May 29 Epub: 2021 May 29 Authors Ridyard KE , Overhage J , |
|
|
In vitro activity of the antimicrobial peptides h-Lf1-11, MSI-78, LL-37, fengycin 2B, and magainin-2 against clinically important bacteria. ✅
Go to Publication ✅
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] (Braz J Microbiol ) Vol: 53 Issue 1 Pages: 171-177 Pub: 2022 Mar Epub: 2021 Nov 4 Authors Denardi LB , de Arruda Trindade P , Weiblen C , Ianiski LB , Stibbe PC , Pinto SC , Santurio JM , |
|
|
The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections. ✅
Go to Publication ✅
BMC infectious diseases (BMC Infect Dis ) Vol: 18 Issue 1 Pages: 17 Pub: 2018 Jan 8 Epub: 2018 Jan 8 Authors Babikir IH , Abugroun EA , Bilal NE , Alghasham AA , Abdalla EE , Adam I , |
|
|
The activity and action mechanism of novel short selective LL-37-derived anticancer peptides against clinical isolates of Escherichia coli. ✅
Go to Publication ✅
Chemical biology & drug design (Chem Biol Drug Des ) Vol: 93 Issue 1 Pages: 75-83 Pub: 2019 Jan Epub: 2018 Oct 3 Authors Aghazadeh H , Memariani H , Ranjbar R , Pooshang Bagheri K , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
